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Background: Insulin is widely used in patients with type 2 diabetes mellitus (T2DM). More attention was focused
on its higher risk of colorectal cancer (CRC). This meta-analysis examined the relationship between levels of insulin
use and the risk of CRC.
Methods: A meta-analysis using data from 12 published epidemiologic studies (7 case–control, and 5 cohort
studies) published before Jan. 2014 was done to examine the association between insulin use and CRC. Random
effects analyses were done to calculate relative risk (RR) and 95% confidence intervals (CI). Heterogeneity among
studies was measured by the χ2 and I2 statistic.
Results: Overall, the risk of CRC was significantly associated with insulin use to a random-effects model (RR, 1.69;
95% CI, 1.25 -2.27). When subgroup analyses were conducted according to the study types, no associations were
detected in cohort group (RR, 1.25; 95% CI, 0.95-1.65; I2, 75.7%); however significant association was detected in
case–control group (RR, 2.15; 95% CI, 1.41-3.26; I2, 89.1%).
Conclusions: A significant harmful effect of insulin, observed mainly among case–control studies, may result from
study design differences and amount of included studies. Although these results suggest a harmful effect of insulin
use for CRC risk, additional large studies are warranted to support these preliminary evidences.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2194715731194123.Background
Colorectal cancer (CRC) is now the second leading cause
of cancer-related death in the developed countries [1].
Previous epidemiological studies showed that smoking, al-
cohol consumption, and obesity are risk factors for co-
lorectal cancer [2]. It was proposed that the effects of
dietary and lifestyle risk factors on CRC may be me-
diated through hyperinsulinemia. Type 2 diabetes mellitus
(T2DM), a condition associated with hyperinsulinemia, is
associated with an increased risk of mortality from a range
of solid tumors, including cancers of the colon, breast
and pancreas [3,4]. Similar associations have been noted
with central obesity and other conditions associated
with increased levels of circulating insulin [5,6]. These* Correspondence: yinshinan2011@163.com
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unless otherwise stated.observations have given rise to the hypothesis that growth
of these tumors, which are characterized by abnormal
expression and function of the insulin–IGF-1 series of re-
ceptors, is promoted by the trophic action of insulin in-
teracting with these receptors [7,8]. Some results showed
that insulin use would increase cancer risk, while others
suggested that insulin did not play a role in cancer devel-
opment. Furthermore, in an animal model, exogenous in-
sulin injection stimulates the growth of colorectal cancer
precursors [9]. In clinical studies, high circulating insulin
levels are independently associated with increased colo-
rectal cancer risk. Patients with T2DM begin to require
insulin therapy when there is significant decline in en-
dogenous insulin production. However, hyperinsulinemia
is actually augmented during this phase by exogenous in-
sulin because of the inefficiency of exogenous insulin.
Based on these observations, we hypothesized that chronic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may promote colorectal cancer development.
Meta-analysis is a useful statistical tool to pool the
relevant studies together and gain a more powerful con-
clusion [10]. The meta-analysis was also used in the
search for potential causes of CRC. For instance, Boyle T
et al. searched MEDLINE and EMBASE for English-
language cohort and case–control studies that examined
associations between physical activity and the risks of
CRC. Through combining twenty-one studies, the re-
sults of the systematic review and meta-analysis suggest
that physical activity is associated with a reduced risk of
CRC, and that the magnitude of the association does not
differ by subsite [11]. Nowadays, the association between
insulin use and risk of CRC is still unclear and a meta-
analysis would provide more powerful evidence. Given
these reasons, the aim of the current meta-analysis and
systematic review was to quantitatively evaluate findings
from observational studies on the insulin use and the in-
cidence of CRC in patients with T2DM.
Methods
Search strategy and inclusion criteria
This meta-analysis was conducted according to the
PRISMA guidelines [12]. We searched PubMed and
EMBASE to retrieve related studies published before
Jan, 2014 and Medical Subject Heading (MeSH) key-
words “colorectal” and “cancer”, “carcinoma”, “neoplasia”,
“tumor” in combine with “insulin”, “antihyperglycemic”.
The citations of related articles were detected for add-
itional publications. When several reports from the same
study were published, only the most recent or informative
one was included in this meta-analysis. The language was
restricted to only English. Contacting to the correspond-
ing authors of retrieved articles was conducted when add-
itional information was needed.
The articles would be considered eligible if the studies
met the inclusion criteria: [1] evaluate the association
between insulin use and risk of CRC; [2] adopt case–
control or cohort study design; [3] provides the odds
ratios (ORs) or relative risks (RRs) with confidence in-
tervals (CI), standard errors or sufficient data to calculate
them.
Data extraction and assessment of study quality
Two reviewers (S.Y and D.J) extracted the data from
each study independently and checked again after the
first extraction. Any disagreements about data extraction
were discussed by two reviewers and resolved finally.
The data extracted from each study contained: name of
first author, study design, study period, country, num-
bers of subjects (cases, controls, or total), adjustments of
the related factors, exposure definition and OR/RR value
with 95% CI.Considering that only observational studies were in-
cluded in this current meta-analysis, the methodological
qualities of the included studies were assessed using the
Newcastle-Ottawa scale (NOS) [13]. The NOS was de-
veloped for the study quality assessment of the observa-
tional studies. It assessed the selection, comparability
and exposure or outcome of a case–control or cohort
study. The maximum of NOS was 9 stars for a study
and the study with over 6 stars was regarded as relatively
high quality. The quality scale was assessed by two re-
viewers (S.Y and D.J) and disagreements were resolved
through discussion with the third reviewer (H.B).
Statistical methods for the meta-analysis
Expected heterogenicity of the methodology, data source
and so on existed in the included studies. Accordingly,
random-effect methods were used to pool the associa-
tion between insulin use and risk of CRC for all analyses
[14]. The effect was combined under the assumption
that ORs were accurate approximations of RRs. When
both adjusted and unadjusted data were available, the
adjusted data (adjusted ORs or RRs with 95% CI) were
used to compare the exposed and unexposed of aspirin
use. If only stratified results (e.g., by CRC subtypes) were
provided, fixed-effect methods were obtained to sum-
marize the results into a single parameter for each study.
Meanwhile, subgroup analyses were carried out by study
designs and sites. Statistical heterogeneity across studies
was evaluated by both the χ2 and I2 tests. If P < 0.1 and
I2 > 50%, the interstudy heterogeneity was regarded sta-
tistically significant. When the heterogeneity couldn’t be
ignored, subgroup analyses and meta-regression would
be conducted to explore the source of heterogeneity.
Sensitivity analyses were conducted to detect the ro-
bustness of the outcome. After excluding the studies
with lower NOS scale, the studies with higher quality
were included in the sensitivity analyses. Meanwhile,
sensitivity analyses were conducted by changing the
fixed-effect methods to random-effect methods. Poten-
tial publication bias was assessed via both visually evalu-
ating a funnel plot and the Egger test [15,16]. All the
analyses were conducted using the Stata software pack-
age (version 12.0; Stata Corp., College Station, TX).
Results
Identification and selection of studies
The initial 2109 articles (986 from PubMed and 1123
from Emabse) were identified. Besides, 89 articles were
included from reviewing the reference lists of the related
articles. After 1778 duplicates and 364 unrelated articles
were excluded, 56 full-text articles were assessed for eli-
gibility. Among the 56 articles, 32 articles that didn’t re-
port the incidence of CRC and 12 articles that didn’t
report insulin intake were excluded. In final, 12 studies
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provides a flow of search results.
Study characteristics and quality
A total of 491384 individuals were included in this
current meta-analysis. The characteristics of these in-
cluded studies were demonstrated in Table 1. Among
the 12 included studies, 7 studies were case–control
studies and 5 studies were cohorts. Geographic distri-
bution of all included studies was 5 in Americas, 3 in
European and 4 in Asia. To evaluate the methodological
qualities of the included studies, the NOS method was
used in current meta-analysis. The NOS quality assess-
ment score of the most studies was > 6 (mean: 6.83;
standard deviation: 1.23) and only one study got a less
than 6 stars because the shortages in data source or
methodological designs.
Insulin use and risk of CRC
Figure 2 shows the effect of insulin use and risk of CRC.
In a random-effects meta-analysis, the use of insulin was
associated with increased risk of CRC (RR, 1.69; 95% CI,
1.25 -2.27; I2, 91.8%). Table 2 displayed the effects of
insulin use and CRC risk in subgroup analysis by study
designs and sites. When subgroup analyses were con-
ducted according to the study types, no associations
were detected in cohort group (RR, 1.25; 95% CI, 0.95-
1.65; I2, 75.7%); however significant association was
detected in case–control group (RR, 2.15; 95% CI, 1.41-
3.26; I2, 89.1%).The significant association between in-
sulin use and CRC risk was detected in the studies in
America (RR, 1.73; 95% CI, 1.15-2.60; I2 = 67.8%) andFigure 1 Flow chart of the literature search. The literature search was c
studies were reviewed as well.Asia (RR, 2.55; 95% CI, 2.14-3.04; I2 = 3.9%). No signifi-
cant from the studies from Europe was found (RR, 1.20;
95% CI, 0.92-1.57; I2 = 85.8%). When the gender was
considered, however, no association was detected in nei-
ther male nor female group. However this result should
be considered in caution considering that only 3 studies
were included in each group (Table 3).
A significant heterogeneity was observed when all the
12 studies were included (I2, 91.8%; P < 0.001). However,
the heterogeneity was significant in subgroup analyses of
cohort (I2, 75.7%; P = 0.002) and case–control studies (I2,
91.8%; P < 0.001). A sensitivity analysis was conducted
after one study which got NOS < 6 stars was excluded
and no change of result was observed (RR, 1.65; 95% CI,
1.27 -2.12; I2, 87.8%). There was also no change when a
fixed-effect method was obtained with all the 12 studies
included (RR, 1.35; 95% CI, 1.26 - 1.45; I2, 91.8%). No
significant publication bias was found in the selected 12
studies (Begg’s funnel plot, symmetrical; Begg’s test, P
for bias = 0.086; Eegg’s test, P for bias = 0.235).
Discussion
With the high incidence rate of CRC and very poor
prognosis associated with the diagnosis, identification of
potential chemopreventive agents is highly desirable.
Previous studies showed that aspirin, NSAIDs and sta-
tins therapy may be associated with reduced risk of
CRC. While insulin is a usually used medicine in the
clinic, it is important to detect the effect of insulin use
on the risk of CRC. In the present meta-analysis, we ob-
served a significant 69% increased risk of CRC asso-
ciated with insulin use by combining results from 12onducted in Medline and EMBASE. The reference lists of the relevant
Table 1 Study characteristics of included cohort and case–control studies on insulin use and CRC risk






Gender Confounders for adjustment
Campbell 2010 [17] 1992-2007 Cohort USA 184,194 2,474 ≥4 years M/F 1, 3, 4, 5, 6, 7, 8, 20
Carstens 2012 [18] 1995-2009 Cohort Denmark 22,826 320 NR M/F 1, 9, 10
Chang 2012 [19] 2000-2007 C-C China 108,920 468 ≥2 years M/F 11, 12, 13, 14, 15, 16, 17
Chung 2008 [20] 2003-2006 C-C Korea 325 100 NR M/F 1, 2
Currie 2009 [21] 2000–2009 Cohort UK 62,809 292 NR M/F 1, 2, 18, 19
Gu 2013 [22] 2001-2010 Cohort China 8,774 31 NR M/F 1,2, 11, 18,
Hsieh 2012 [23] 2000-2008 C-C China 61,777 1,739 NR M/F 1, 2
Koro 2007 [24] 1997–2004 C-C USA 2,435 408 NR M/F 1, 2, 9, 10
Onitilo 2013 [25] 1995-2009 Cohort USA 9,486 106 NR M/F 1, 3, 11, 12
Vinikoor 2009 [26] 1996-2006 C-C USA 3,752 1,688 ≥1 years M/F 1,2, 5, 7, 20, 21
Wong 2012 [27] 1998-2007 C-C USA 1,168 196 ≥3 years M/F 1, 2
Yang 2004 [28] 1987-2002 C-C UK 24,918 125 ≥5 years M/F 2, 3, 5, 8, 11, 18
C-C: Case–control study; M: male; F: female.
The adjusteted factors are: (1) age, (2) gender, (3) body mass index, (4) physical activity, (5) nonsteroidal anti-inflammatory drug use, (6) alcohol use, (7) family
history of colorectal cancer, (8) endoscopy history, (9) current date of follow-up; (10) date of birth (11) use of sulfonylurea, glinides, metformin, thiazolidinediones,
α-glucosidase inhibitors (11) chronic liver disease, (12) nephropathy, (13) statins, β-blocker, calcium channel blockers, (14) cerebrovascular disease,
(15) angiotensin-converting enzyme inhibitors, (16) chronic kidney disease, (17) aspirin, (18) smoking status, (19) diagnosis of a previous cancer; (20) education;
(21), calcium intake.
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tions, which were conducted to investigate the associ-
ation between insulin use and risk of CRC. Nowadays,
much has been known on the role of insulin use in can-
cer, several systematic reviews and meta-analysis, both
on observational and interventional studies, have re-
ported the harmful effect of insulin on cancer.
In our subgroup analyses, there are several interesting
results. The subgroup analyses by the study designs
showed that cohort studies alone showed no association
between insulin use and risk of CRC. Although cohortFigure 2 Forest plot of the association between insulin use and risk o
weight of each study. The horizontal lines represent 95% CIs. The diamond
was obtained.study would avoid the selection bias and provide better
evidence, in this study there were fewer cohorts included
and it might be a possible perturbation of the results.
Besides, the association of insulin use and risk of CRC in
the cohort group was quite closed to the statistical sig-
nificance level. So it is more reasonable to conclude that
insulin use might be a risk of CRC. In the subgroup
analyses by the sites, the result in Europe was different
with the results from Asia and America. This might be
explained by the geographical and ethnic differences.
Besides, the environment, genetic factors and dietaryf CRC. The size of the shaded square is proportional to the percent
data markers indicate the pooled ORs. A random-effect model
Table 2 Quality assessment of included studies 1
Author Quality assessment criteria–Case–control
Selection Comparability Outcome/Exposure Overall quality
Chang et al. 2012 [19] *** ** *** 8
Chung et al. 2008 [20] *** * ** 6
Hsieh et al. 2012 [23] *** ** *** 8
Koro et al. 2007 [24] *** * ** 6
Vinikoor et al. 2009 [26] ** * ** 5
Wong et al. 2012 [27] *** ** ** 7
Yang et al. 2004 [28] *** ** ** 7
Author Quality assessment criteria—Cohort
Selection Comparability Outcome/Exposure Overall quality
Campbell et al. 2010 [17] ** ** *** 7
Carstensen et al. 2012 [18] *** ** *** 8
Currie et al. 2009 [21] ** ** ** 6
Gu et al. 2013 [22] *** ** *** 8
Onitilo et al. 2013 [25] ** ** ** 6
1 the methodological qualities of the included studies were assessed using the Newcastle-Ottawa scale.
*One point; **two points; ***three points.
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analyses by the gender showed that no association be-
tween both gender groups was detected. The reason of
this outcome was that only 3 studies reported the data
stratified by the genders. More well-designed studies are
wanted for advanced research.
The potential biological mechanisms that relate insulin
and CRC have been studied in several studies. There is
evidence suggesting that diabetes is an independent risk
factor for colorectal cancer; a meta-analysis showed an
overall positive association [29]. Insulin, which is usually
used in patients with T2DM, might provide certain role
in the increased risk of CRC; concurrently diabetes situ-
ation might be associated with the contribution of insulinTable 3 Subgroup analysis of insulin use and CRC
incidence with combined RR
No. of
studies
Summary effect Study heterogeneity
RR 95% CI P I2
Study design
Cohort 5 1.25 0.95-1.65 0.002 75.7
Case–control 7 2.15 1.41-3.26 <0.001 89.1
Geographic location
Europe 3 1.20 0.92-1.57 0.001 85.8
America 5 1.73 1.15-2.60 0.014 67.8
Asia 4 2.55 2.14-3.04 0.373 3.9
Gender
Male 3 1.02 0.90-1.16 0.512 0.0
Female 3 1.14 0.73-1.77 0.026 72.5
RR, relative risk; CI, confidence interval.on the increasing risk of CRC. Insulin and IGF-1 stimulate
cellular proliferation; IGF-1 can inhibit apoptosis [28].
Enhanced proliferation of mutated cells or failure to
eliminate aberrant cells may contribute to colorectal car-
cinogenesis. We have previously shown that elevated insu-
lin may contribute to the development of adenomas, the
precursors to most colorectal cancer [30].
The strengths of this study include the comprehensive
and systematic literature search of observational studies
consistency of association between insulin and CRC,
ability to evaluate the potential influence of measured
confounders on the summary estimates. The likelihood
of important selection or publication bias in our meta-
analysis is small. During the identification and selection
process, we did not exclude any article because of meth-
odological characteristics. With the larger number of
studies, we were able to carry out multiple subgroup
analyses, evaluate heterogeneity and the presence of
publication bias.
We aimed to conduct a rigorous meta-analysis; how-
ever, several limitations should be acknowledged. First,
several of the included studies enrolled diabetic men
from different ethnicities in the same geographic region.
Our subgroup analysis was conducted according to re-
gion instead of ethnicity. Race has been reported to be
one of the strongest risk factors for diabetes mellitus;
however, since regional variation in diet is also a con-
founding factor for DM, we chose to consider location
only. Secondly, we did not consider the associations be-
tween insulin use and CRC subtypes since there was
limited data on this in the included studies, and it pre-
vented classification of the subtypes. Finally, language
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search included studies written in English only. This de-
cision was based on the difficulty for us to retrieve all
available literature in all languages.
Conclusions
In conclusion, this meta-analysis supports an association
between insulin use and CRC risk. To further elucidate
this relationship, efforts to quantify insulin dose and
duration on the CRC risk at the individual level in large
observational studies or randomized trials are needed.
These are fundamental steps before suggesting a better
and more reasonable insulin strategy to patients with
T2DM.
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